 |
 |
|
|
|
RESÚMENES ABRIL 2010 |
Schizophrenia-Psychotic
Disorders & Antipsychotics
(Haga un click en la
información del journal
para acceder al resúmen)
5
– doble-ciego o
metanálisis; 4 – subanálisis o estudio
aleatorizado; 3
– revisión, abierto, básico; 2 –
casos; 1 – opinión
GRATIS = Texto
gratuito en algunos países de la región iberoamericana
3! - Duration
of untreated illness and outcome in schizophrenia: test of predictions in
relation to relapse risk
David
Cunningham Owens, Eve C. Johnstone, Patrick Miller, J. Fiona Macmillan, Timothy
J. Crow
The British Journal of Psychiatry (2010) 196: 296-301
GRATIS 5 - The clinical and cost effectiveness of testing for
cytochrome P450 polymorphisms in patients treated with antipsychotics: a
systematic review and economic evaluation
Fleeman N, McLeod C, Bagust A, Beale S, Boland A,
Dundar Y, et al.
Health Technol Assess 2010;14(3)
3 - Roles of the Akt/GSK-3 and Wnt Signaling Pathways in
Schizophrenia and Antipsychotic Drug Action
Zachary Freyberg, Stephen J.
Ferrando, and Jonathan A. Javitch
Am J Psychiatry 2010;
167:388-396
3! - Anterior internal capsule
volumes increase in patients with schizophrenia switched from typical
antipsychotics to olanzapine
V. M.
Goghari, D. J. Lang, B. Khorram, J. Götz, R. A. Vandorpe, G. N. Smith, L. C.
Kopala, A. M. Barr, and W. G. Honer*
Journal
of Psychopharmacology. First published on April 1, 2010
3! - Emotion processing in
schizophrenia: fMRI study of patients treated with risperidone long-acting
injections or conventional depot medication
Simon A.
Surguladze, Elvina M. Chu, Nicolette Marshall, Anthony Evans, Anantha PP
Anilkumar, Clive Timehin, Colm McDonald, Christine Ecker, Mary L. Phillips, and
Anthony S. David
Journal of Psychopharmacology. First published on
April 1, 2010
3! - Association of
Community-Acquired Pneumonia With Antipsychotic Drug Use in Elderly Patients. A Nested Case–Control Study
Gianluca Trifirò, Giovanni Gambassi, Elif F. Sen, Achille P. Caputi, Vincenzo Bagnardi, Jose Brea, and Miriam C.J.M. Sturkenboom
Ann Intern Med April 6, 2010 vol. 152 no. 7 418-425
5 - The Effect of Metformin on
Anthropometrics and Insulin Resistance in Patients Receiving Atypical
Antipsychotic Agents: A Meta-Analysis
Megan
Ehret, John Goethe, Michael Lanosa, and Craig I. Coleman
3 - Safety and efficacy of long-acting injectable
risperidone in daily practice: an open-label, noninterventional, prospective
study in schizophrenia and related disorders
Parellada, Eduard; Kouniakis,
Filippos; Siurkute, Aldona; Schreiner, Andreas; Don, Liana
International
Clinical Psychopharmacology: May 2010 - Volume 25 - Issue 3 - pp 149-154
4 - Medication satisfaction in schizophrenia: a
blinded-initiation study of paliperidone extended release in patients
suboptimally responsive to risperidone
Canuso,
Carla M; Grinspan, Augusto; Kalali, Amir; Damaraju, Chandrasekharrao Venkata;
Merriman, Ursula; Alphs, Larry; Awad, Awad George
International
Clinical Psychopharmacology: May 2010 - Volume 25 - Issue 3 - pp 155-164
3! - Plasma orexin A, ghrelin, cholecystokinin, visfatin,
leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode
male patients with psychosis
Basoglu,
Cengiz; Oner, Ozgur; Gunes, Cengiz; Semiz, Umit B; Ates, Alpay M; Algul, Ayhan;
Ebrinc, Servet; Cetin, Mesut; Ozcan, Omer; Ipcioglu, Osman
International
Clinical Psychopharmacology: May 2010 - Volume 25 - Issue 3 - pp 165-171
4< - Long-term symptomatic remission of schizophrenia with
once-daily extended release quetiapine fumarate: post-hoc analysis of data from
a randomized withdrawal, placebo-controlled study
Peuskens,
Joseph; Trivedi, Jitendra K.; Brecher, Martin; Miller, Frank; on behalf of the
Study 4 Investigators
International
Clinical Psychopharmacology: May 2010 - Volume 25 - Issue 3 - pp 183-187
3 - The effect of sertindole on QTD and TPTE
J. Nielsen, M.
P. Andersen, C. Graff,
J. K. Kanters,
T. Hardahl,
J. Dybbro,
J. J. Struijk,
J. M. Meyer,
E. Toft
Acta Psychiatrica Scandinavica.
Volume 121 Issue 5, Pages 385 - 388
3! - A retrospective evaluation of the impact of total smoking
cessation on psychiatric inpatients taking clozapine
I. Cormac, A. Brown, S. Creasey, M. Ferriter, B. Huckstep
Acta Psychiatrica Scandinavica.
Volume 121 Issue 5, Pages 393 - 397
3! - Carriers of the UGT1A4 142T>G gene variant are
predisposed to reduced olanzapine exposure—an impact similar to male gender or
smoking in schizophrenic patients
Roza Ghotbi,
Buster Mannheimer, Eleni Aklillu, Akira Suda,
Leif Bertilsson, Erik Eliasson and Urban Ösby
European Journal of Clinical Pharmacology. Volume 66,
Number 5 / May, 2010: 465-474
3 - A Common Polymorphism in the Cannabinoid Receptor 1 (CNR1) Gene is
Associated with Antipsychotic-Induced Weight Gain in Schizophrenia
Arun
K Tiwari, Clement C Zai, Olga Likhodi, Annika Lisker,
Deepika Singh, Renan P Souza, Poonam Batra, Syed H E Zaidi,
Sheng Chen, Fang Liu, Imke Puls, Herbert Y Meltzer, Jeffrey
A Lieberman, James L Kennedy and Daniel J Müller
Neuropsychopharmacology
(2010) 35, 1315–1324
3 - Pergolide
Treatment of Cognitive Deficits Associated with Schizotypal Personality
Disorder: Continued Evidence of the Importance of the Dopamine System in the
Schizophrenia Spectrum
Margaret
M McClure, Philip D Harvey, Marianne Goodman,
Joseph Triebwasser, Antonia New, Harold W Koenigsberg, Larry
J Sprung, Janine D Flory and Larry J Siever
Neuropsychopharmacology (2010) 35, 1356–1362
3 - Dopamine D2 receptor
occupancy by perospirone: a positron emission tomography study in patients with
schizophrenia and healthy subjects
Ryosuke Arakawa,
Hiroshi Ito, Akihiro Takano, Masaki Okumura,
Hidehiko Takahashi, Harumasa Takano, Yoshiro Okubo and
Tetsuya Suhara
Psychopharmacology. Volume
209, Number 4 / May, 2010: 285-290
4! - Challenging the assumption that improvement in functional
outcomes is delayed relative to improvement in symptoms in the treatment of
schizophrenia
Bruce J. Kinon, Lei Chen, Haya Ascher-Svanum, Virginia L. Stauffer, Sara
Kollack-Walker, Wei Zhou, Shitij Kapur, John M. Kane and Dieter Naber
Schizophrenia
Research. Volume
118, Issues 1-3, May 2010, Pages 176-182
3! -
Time course of antipsychotic treatment response in schizophrenia: Results from
a naturalistic study in 280 patients
M. Jäger, M. Riedel, M.
Obermeier, R. Schennach-Wolff, F. Seemüller, T. Messer, G. Laux, H. Pfeiffer,
D. Naber, L.G. Schmidt, W. Gaebel, J. Klosterkötter, I. Heuser, K.-U Kühn, M.R.
Lemke, E. Rüther, S. Klingberg, M. Gastpar, R. Bottlender and H.-J. Möller
Schizophrenia
Research. Volume
118, Issues 1-3, May 2010, Pages 183-188
3 - Switching schizophrenia patients from typical
neuroleptics to aripiprazole: Effects on working memory dependent functional
activation
Florian Schlagenhauf,
Martin Dinges, Anne Beck, Torsten Wüstenberg, Eva Friedel, Theresa Dembler,
Rahul Sarkar, Jana Wrase, Jürgen Gallinat, Georg Juckel and Andreas Heinz
Schizophrenia
Research. Volume
118, Issues 1-3, May 2010, Pages 189-200
3! -
Quality assessment and comparison of evidence for electroconvulsive therapy and
repetitive transcranial magnetic stimulation for schizophrenia: A systematic
meta-review
S.L.
Matheson, M.J. Green, C. Loo and
V.J. Carr
Schizophrenia
Research. Volume
118, Issues 1-3, May 2010, Pages 201-210
5 -
Topiramate for prevention of olanzapine associated weight gain and metabolic
dysfunction in schizophrenia: A double-blind, placebo-controlled trial
Preeta
Kaur Narula, H.S. Rehan, K.E.S. Unni and Neeraj Gupta
Schizophrenia
Research. Volume
118, Issues 1-3, May 2010, Pages 218-223
3! - Nonresponse to clozapine and premorbid functioning
in treatment refractory schizophrenia
Deanna L. Kelly,
Stephanie Feldman, Douglas L. Boggs, Elizabeth Gale and Robert R. Conley
Comprehensive Psychiatry. Volume 51, Issue 3, May-June 2010,
Pages 298-302
4 - Does Therapeutic
Equivalence Follow Bioequivalence? A Randomized Trial to Assess Clinical
Effects After Switching From Clozaril to Generic Clozapine (Gen-Clozapine)
Oloruntoba
Oluboka, Sandra Stewart, Suzette Landry, and Susan Adams
J Clin Pharmacol 2010 50: 531 -535
5< - Effects of add-on
mirtazapine on neurocognition in schizophrenia: a double-blind, randomized,
placebo-controlled study
Jan-Henry Stenberg, Viatcheslav
Terevnikov, Marina Joffe, Jari Tiihonen, Evgueni Tchoukhine, Mark Burkin and Grigori
Joffe
The
International Journal of Neuropsychopharmacology (2010), 13:433-441
5 - A randomized,
double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for
schizophrenia
Hsien-Yuan Lane, Ching-Hua
Lin, Yu-Jhen Huang, Chun-Hui Liao, Yue-Cune Chang and Guochuan E. Tsai
The
International Journal of Neuropsychopharmacology (2010), 13:451-460
4 - Orally Disintegrating and
Oral Standard Olanzapine Tablets Similarly Elevate the Homeostasis Model
Assessment of Insulin Resistance Index and Plasma Triglyceride Levels in 12
Healthy Men: A Randomized Crossover Study
Solrun
Vidarsdottir, Pauline Vlug, Ferdinand Roelfsema, Marijke Frölich, and Hanno
Pijl
4< - A Randomized Controlled
Trial of Risperidone and Olanzapine for Schizophrenic Patients With
Neuroleptic-Induced Tardive Dyskinesia
Hung-Yu
Chan, Shu-Chuan Chiang, Ching-JuiChang, Susan S.-F. Gau, Jiahn-Jyh Chen, Chiung-HsuChen,
Hai-Gwo Hwu, and Mei-Shu Lai
3 - Iloperidone for the Treatment of Schizophrenia
The Annals of
Pharmacotherapy: Vol. 44, No. 5, pp. 863-870
3! - Early intervention with second-generation antipsychotics
in first-episode psychosis: results of an 8-week naturalistic study
Richard C. Josiassen, Rita A. Shaughnessy, Dawn M. Filymer, Ann Marie Donohue, Margit Kacso, Naomi Finkel, Jessica Curtis, Brett Audino and Nina Skuban
Early Intervention in Psychiatry. Volume 4 Issue 1, Pages 57 - 63
4 - Paliperidone extended-release tablets in patients
with recently diagnosed schizophrenia
Carla M. Canuso, Cynthia A. Bossie, Joan Amatniek, Ibrahim Turkoz, Gahan Pandina and Barbara Cornblatt
Early Intervention in Psychiatry. Volume 4 Issue 1, Pages 64 - 78
3 - What factors are related to delayed treatment in
individuals at high risk for psychosis?
Young-Chul Chung, Hee-Yeon Jung, Sung-Wan Kim, Seung-Hwan Lee, Sang-Eun Shin, Yun-Mi Shin, Jong-Ik Park, Suk K. An and Young-Hoon Kim
Early Intervention in Psychiatry. Volume 4 Issue 2, Pages 124 - 131
3 - Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in
striatal sub-regions
Felice Iasevoli, Germano Fiore, Maria Cicale,
Giovanni Muscettola and Andrea de Bartolomeis
Psychiatry Research. Volume 177, Issues 1-2, 15 May 2010, Pages 255-260
3 - N-desmethylclozapine (NDMC) is an antagonist at the
human native muscarinic M1 receptor
David R. Thomas, Adeshola Dada, Gareth A. Jones, Rudolf
A. Deisz, Sylvain Gigout, Christopher J.
Langmead, Tim D. Werry, Nicola Hendry, Jim J. Hagan, Ceri H. Davies and Jeannette
M. Watson
Neuropharmacology. Volume 58, Issue 8, June 2010, Pages 1206-1214
3 - Neuroleptic malignant syndrome and its controversies
Branimir Margetic, Branka Aukst Margetic
Pharmacoepidemiology
and Drug Safety. Volume 19 Issue 5, Pages 429 - 435
3 - Establishing remission and good clinical functioning
in schizophrenia: Predictors of best outcome with long-term risperidone
long-acting injectable treatment
M. Lambert, T. De Marinis, J. Pfeil,
D. Naber and A. Schreiner
European
Psychiatry. Volume
25, Issue 4, May 2010, Pages 220-229
3 - Are catatonia and neuroleptic malignant syndrome
related conditions?
S. Vesperini, F. Papetti and D.
Pringuey
L'Encéphale.
Volume 36,
Issue 2, April 2010, Pages 105-110
| Regresar a RESÚMENES ABRIL 2010 |
©
1999-2010 Jorge M Tamayo, MD, BMSS
Creada en Enero 1999
| Declaración: El contenido de esta página web está basado en las revisiones de la literatura realizadas por el autor y las colaboraciones enviadas por los lectores. Este sitio de Internet está dirijido únicamente a profesionales de la salud en Iberoamérica. Si usted es residente de Estados Unidos de América o Europa, debe tener en cuenta que los contenidos no han sido escogidos con base en información aprobada por la FDA o la EMEA |